Shilpa Medicare Ltd has been restrained by the Delhi High Court from manufacturing and exporting Ruxolitinib, following a patent infringement injunction. The order impacts its oncology portfolio and raises investor concerns. The company is expected to contest the ruling while focusing on other therapeutic segments and international markets.
Show moreStay Ahead – Explore Now! Innovators Facade Wins Rs 57.63 Crore Order For Pune Mixed-Use Project
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
